Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Operating Cash Flow

Cash generated by the company's core business operations during the period.

Valneva SENASDAQ: VALN

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow dips below year-ago levels

Q1 FY2026 operating cash flow of €313K (cash outflow) fell 96.2% year over year, behind the +43.8% change in trailing-twelve-month operating cash flow. Sequentially, it fell 99.3% from the prior quarter. Over 3 fiscal years it compounded at -40.0% a year.

Context

  • Operating cash flow amounted to 30.3% of revenue in FY2025, down 9.4 pp from a year earlier.
  • Operating cash flow grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -96.2% toward the trailing-twelve-month pace of +43.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€313K-99.3% QoQ
Last fiscal yearDec 2025
-€52.89M-21.3% YoY
LTMMar 2026
-€67.49M+43.8% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-96.2%——
1 year-21.3%——
3-year CAGR-40.0%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

EUR · from the cash flow

Latest · FY2025
(52.89M) EUR
Year-over-year change
+21.3%

Operating Cash Flow vs competitors

How VALN compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +43.8% is the 2nd highest of 8, against a peer median of -10.8%.
  • Operating cash flow amounts to 43.2% of revenue for VALN, versus a peer median of 129.2%.
VALN Competitors
Operating Cash Flow for VALN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$1.76B USD-10.8%—69.9%
PCVXVaxcyte, Inc.LTM Jun 2026$1.16B USD+152.8%+56.6%—
VIRVir Biotechnology, Inc.LTM Mar 2026$446.05M USD+7.5%—681.0%
IBRXImmunityBio, Inc.LTM Sep 2026$287.56M USD-10.1%-3.3%157.5%
NVAXNovavax, Inc.LTM Mar 2026$91.56M USD-51.6%-16.2%15.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$83.35M USD-18.4%-25.7%—
VALNValneva SELTM Mar 2026€67.49M EUR+43.8%-40.0%43.2%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$58.57M USD-34.4%—129.2%
Peer median (excluding VALN) —-10.8%-9.8%129.2%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
Deferred Income Tax3.45M(1.54M)2.8M761K1.07M
Stock-Based Compensation14.51M(8.66M)5.11M7.98M9.53M
Change in Working Capital36.13M(145.98M)(145.06M)(11.57M)(148K)
Accounts Receivables(21.35M)12.4M(2.86M)15.71M13.33M
Inventory(92.37M)84.22M(9.17M)(6.8M)1.03M
Accounts Payables35.24M(14.05M)(17.4M)00
Other Working Capital114.61M(228.55M)(115.65M)(20.48M)(14.51M)
Other Non-Cash Items81.96M33.07M18.25M(71.72M)30.09M
Operating Cash Flow76.9M(245.34M)(202.74M)(67.22M)(52.89M)
Capital Expenditures(93.17M)(29.32M)(14.31M)(16.44M)(4.48M)
Acquisitions (Net)08K(10.95M)00
Purchases of Investments00000
Sales of Investments0000841K
Other Investing Activities55K260K4.6M90.78M1.87M
Investing Cash Flow(93.12M)(29.05M)(20.59M)76.92M(1.71M)
Debt Repayment(3.9M)34.49M75.89M(6.49M)61K
Common Stock Issued166.82M189.84M0030M
Common Stock Repurchased00(240K)00
Dividends Paid00000
Other Financing Activities(8.42M)(9.21M)(12.57M)(19.97M)(30.69M)
Financing Cash Flow154.5M215.12M63.08M30.68M(621K)
Effect of Forex Changes3.96M(828K)(204K)1.81M(3.4M)
Net Change in Cash142.29M(57.21M)(160.45M)42.19M(58.62M)
Free Cash Flow(16.27M)(274.67M)(217.06M)(83.66M)(57.38M)

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.